TB, HIV, and hepatitis C virus (HCV) share a global presence and propensity to disproportionately affect marginalized populations. However, over recent decades, many fewer drugs have been brought to market for TB than for the others.
Using case examples of drugs developed recently for TB, HIV, and HCV, a study published in PLOS ONE explored possible reasons for that.